Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Capital expenditures by Quarter
Capital expenditures (Form 8-K Selected Cash Flow Information, $M) ($M)
Gilead Sciences Capital expenditures: $140M in Q2 2026, up 30.8% from a year earlier.
Latest, Q2 2026
140
Period ended Jun 30, 2026
Change on a year earlier
+30.8%
107 in Q2 2025
History
26 quarters
Since Q1 2020
Sources
22
Documents cited below
Where the Q2 2026 figure comes from
“|| Purchases of property, plant and equipment | (140) | (107) | (257) | (211)”
Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Reported in Form 8-K Selected Cash Flow Information.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Gilead Sciences Capital expenditures ($M), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rel-capex-row
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.